Quick Answer
Royalty Pharma plc reported Long-Term Debt of $8.57 billion for fiscal year 2025.
Royalty Pharma plc Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $8.57B | +29.6% |
| 2024 | $6.61B | +7.8% |
| 2023 | $6.14B | +0.3% |
| 2022 | $6.12B | -13.8% |
| 2021 | $7.10B | +22.0% |
| 2020 | $5.82B | -2.3% |
| 2019 | $5.96B | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.57B | +29.6% | +22.3% |
| June 30, 2025 | $7.00B | -7.9% | +5.8% |
| March 31, 2025 | $6.62B | +7.8% | +0.1% |
| December 31, 2024 | $6.61B | +7.8% | +0.1% |
| September 30, 2024 | $6.61B | +7.8% | -13.0% |
| June 30, 2024 | $7.60B | +24.1% | +23.8% |
| March 31, 2024 | $6.14B | +0.3% | +0.1% |
| December 31, 2023 | $6.14B | +0.3% | +0.1% |
- Royalty Pharma plc showed an increase of +29.6% in Long-Term Debt compared to the prior fiscal year.
- Over the 2019–2025 period, Royalty Pharma plc’s long-term debt has grown by 43.9% (from $5.96 billion to $8.57 billion).
- The most recent figure is from Royalty Pharma plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: